Float Short %

14.16

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-2.48

EPS Last/This Y

EPS This/Next Y

10.75

Price

2.45

Target Price

24.33

Analyst Recom

Performance Q

-76.57

Upside

-86,134.6%

Beta

1.72

Ticker: MBRX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	MBRX	4.63	N/A	N/A	0
2026-01-26	MBRX	4.56	N/A	N/A	0
2026-01-27	MBRX	4.45	N/A	N/A	0
2026-01-28	MBRX	4.52	N/A	N/A	0
2026-01-29	MBRX	4.23	N/A	N/A	0
2026-01-30	MBRX	4.23	N/A	N/A	0
2026-02-02	MBRX	4.04	N/A	N/A	0
2026-02-03	MBRX	4.19	N/A	N/A	0
2026-02-04	MBRX	4.22	N/A	N/A	0
2026-02-05	MBRX	3.91	N/A	N/A	0
2026-02-06	MBRX	4.26	N/A	N/A	0
2026-02-09	MBRX	4.11	N/A	N/A	0
2026-02-10	MBRX	4.18	N/A	N/A	0
2026-02-11	MBRX	4.22	N/A	N/A	0
2026-02-12	MBRX	4.22	N/A	N/A	0
2026-02-13	MBRX	4.4	N/A	N/A	0
2026-02-17	MBRX	4.65	N/A	N/A	0
2026-02-18	MBRX	4.79	N/A	N/A	0
2026-02-20	MBRX	2.44	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	MBRX	4.63	-	-0.8	-132.00
2026-01-26	MBRX	4.55	-	-1.7	-132.00
2026-01-27	MBRX	4.42	-	-3.0	-132.00
2026-01-28	MBRX	4.61	-	-2.1	-132.00
2026-01-29	MBRX	4.27	-	-0.6	-132.00
2026-01-30	MBRX	4.22	-	-4.2	-132.00
2026-02-02	MBRX	4.05	-	-2.3	-132.00
2026-02-03	MBRX	4.12	-	-1.8	-132.00
2026-02-04	MBRX	4.20	-	-1.0	-132.00
2026-02-05	MBRX	3.93	-	2.6	-132.00
2026-02-06	MBRX	4.31	-	-5.5	-132.00
2026-02-09	MBRX	4.13	-	-2.3	-132.00
2026-02-10	MBRX	4.20	-	-2.8	-132.00
2026-02-11	MBRX	4.15	-	-0.7	-132.00
2026-02-12	MBRX	4.22	-	-2.0	-132.00
2026-02-13	MBRX	4.39	-	-2.7	-132.00
2026-02-17	MBRX	4.54	-	-5.5	-132.00
2026-02-18	MBRX	4.79	-	-4.9	-132.00
2026-02-19	MBRX	2.67	-	-	-132.00
2026-02-20	MBRX	2.45	-	-	-132.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	MBRX	0.00	1.36	5.64
2026-01-26	MBRX	0.00	1.31	5.64
2026-01-27	MBRX	0.00	1.31	5.64
2026-01-28	MBRX	0.00	1.31	11.78
2026-01-29	MBRX	0.00	1.31	11.78
2026-01-30	MBRX	0.00	1.31	11.78
2026-02-02	MBRX	0.00	1.31	11.82
2026-02-03	MBRX	0.00	1.31	11.82
2026-02-04	MBRX	0.00	1.31	11.82
2026-02-05	MBRX	0.00	1.31	11.82
2026-02-06	MBRX	0.00	1.31	11.82
2026-02-10	MBRX	0.00	1.43	11.82
2026-02-11	MBRX	0.00	1.43	14.16
2026-02-12	MBRX	0.00	1.43	14.16
2026-02-13	MBRX	0.00	1.43	14.16
2026-02-17	MBRX	0.00	0.65	14.16
2026-02-18	MBRX	0.00	0.65	14.16
2026-02-19	MBRX	0.00	0.65	14.16
2026-02-20	MBRX	0.00	0.65	14.16
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.68

Avg. EPS Est. Current Quarter

-7.75

Avg. EPS Est. Next Quarter

-3.16

Insider Transactions

Institutional Transactions

0.65

Beta

1.72

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.9

Max Drawdown 5-Year %

-99.9

Target Price

24.33

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-60.47

Average EPS Est. Cur. Y

-132

EPS Next Y. (Est.)

-121.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.65

Return on Equity vs Sector %

162

Return on Equity vs Industry %

179.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Moleculin Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 17

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today

news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance

stock history MBRX – Moleculin Biotech Inc invest stock market

stock prices MBRX premarket after hours

ticker MBRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: MBRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y